A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Suspended
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms iNDiGO
  • Sponsors NeuroDerm
  • Most Recent Events

    • 18 Apr 2018 According to a Mitsubishi Tanabe Pharma America media release, data from his trial will be presented at at the 70th Annual Meeting of the American Academy of Neurology (AAN) 2018.
    • 06 Jun 2017 According to a NeuroDerm media release, the company has received a Scientific Advice Letter from the Scientific Advice Working Party of the European Medicines Agency (EMA). The letter accepts the main design elements suggested by NeuroDerm for the amended version of this trial, including study population and primary and secondary endpoints, as well as the suggested statistical analysis approach.
    • 11 May 2017 According to a NeuroDerm media release, trial completion expected in parallel with BeyoND study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top